Rat Models of Dry AMD in the MICRON Literature
About the MICRON Research Literature
These research pages organize published studies using MICRON imaging systems by animal species and the disease or condition investigated.
All publication counts and figures reflect the complete indexed research collection.
Explore related studies through the MICRON Research Hubs or search the complete publication collection in the reSEARCH portal.
Understanding Dry AMD
Atrophic AMD involves loss of photoreceptors, retinal pigment epithelium and choriocapillaris.
Atrophy and neovascularization can coexist in the same eye.
Dry AMD in Experimental Research
Without an exudative component there is usually no leakage to image, so assessment turns on what remains of the retina and how well it works:
- Layer thickness and lesion area by cross-sectional imaging and autofluorescence
- Function by electrophysiological or behavioral measures
Species without a macula model particular degenerative processes and AMD-like endpoints rather than the macular anatomy of human geographic atrophy.
Rat Models of Dry AMD
The rat offers a larger eye than the mouse while remaining a small-animal model, which eases injection and imaging without moving to a large species.
Published MICRON Research: Dry AMD in Rats
This page lists 6 papers from the MICRON literature, published 2017 to 2026, that study atrophic (dry) age-related macular degeneration in rats.
Of these publications:
- 6 studies used rats as the primary dry age-related macular degeneration disease model.
Scope of the literature collection: Publication counts reflect studies identified and indexed in the MICRON research corpus. This collection is not intended to represent an exhaustive review of all published dry age-related macular degeneration research.
Which imaging and experimental techniques are used in these studies?
| Technique | Papers |
|---|---|
| Optical Coherence Tomography | 6 |
| Electroretinography | 4 |
| Fundus Fluorescein Angiography | 3 |
| Intravitreal Injection / Delivery | 2 |
| AAV-Mediated Ocular Gene Delivery | 1 |
| Laser Photocoagulation Models | 1 |
| Optokinetic / Optomotor Response | 1 |
| RPE Cell Transplantation | 1 |
| Topical Ophthalmic Drug Delivery | 1 |
Technique counts are paper-level co-occurrences and do not necessarily indicate that a technique was applied to the focal species or focal disease model.
Capabilities and Limitations of Imaging Techniques
A summary of what each imaging technique listed above can measure, the information it provides, and its limitations in research applications.
Optical Coherence Tomography
Optical coherence tomography provides high-resolution, cross-sectional images of ocular tissues in the living eye, allowing researchers to visualize structures at different depths. OCT is particularly useful for measuring tissue thickness, identifying structural abnormalities, and assessing the location and extent of tissue changes.
As a non-invasive imaging technique, OCT enables repeated measurements in the same eye over time, supporting longitudinal studies of disease progression and treatment response. Although OCT provides detailed structural information, it does not directly measure cellular activity or visual function. Tissue that appears structurally normal may still have functional abnormalities, making OCT a valuable companion to functional assessments such as electroretinography (ERG).
Electroretinography
Records the retina's electrical response to light, giving component-sensitive information about outer- and inner-retinal function. It measures function directly, which no structural method does. Full-field ERG sums across the whole retina, so a small lesion can leave the trace unchanged; focal and multifocal variants trade signal amplitude for spatial resolution.
Fundus Fluorescein Angiography
Fundus fluorescein angiography uses an injected fluorescent dye to visualize blood flow through the retinal and choroidal circulation. Sequential images show how vessels fill, identify areas of reduced or absent perfusion, and reveal dye leakage associated with vascular abnormalities.
This technique is particularly useful for evaluating vascular perfusion, blood-retinal barrier integrity, and abnormal vessel growth. Fluorescein angiography primarily shows dye distribution rather than the surrounding retinal tissue. It provides a two-dimensional (en face) view in which vessels at different depths may overlap. Cross-sectional and cellular structural details require other imaging methods, such as optical coherence tomography (OCT) or optical coherence tomography angiography (OCT-A). Vascular abnormalities that do not affect dye filling or produce leakage may also remain undetected.
Intravitreal Injection / Delivery
Injection into the vitreous places a substance directly into the vitreous at a known administered dose and chosen time, reducing but not eliminating systemic exposure. The injectate may be a therapeutic compound, cell preparation or viral vector, or an agent used to create the model, such as a toxin, vasoactive or excitotoxic compound, or infectious inoculum. The route bypasses surface-delivery barriers and provides direct access to the vitreous and posterior segment, but the concentration reached in a particular ocular tissue depends on distribution and clearance and is not fixed by the injected dose alone. It is invasive and discrete: each repeat dose or challenge requires another injection, and vehicle- or sham-injected controls can help separate effects of the injectate from effects of the procedure.
AAV-Mediated Ocular Gene Delivery
An adeno-associated viral vector delivers genetic material to ocular cells, and a single administration can support long-lived transgene expression. That persistence is useful for gene augmentation and sustained therapeutic-protein expression; AAV can also deliver gene-silencing or genome-editing cargo, where long-lived expression of the editing machinery may be unnecessary or undesirable. Capsid and route of delivery jointly determine which cells are reached, so different delivery routes and vector designs give different distributions.
Laser Photocoagulation Models
A laser lesion provokes a reproducible, quantifiable injury at a known time and place. Wavelength, power, duration, spot size, pulse mode, focus and lesion location together determine the injury produced, allowing laser exposure to be configured for different experimental endpoints. It is an induced injury, not the disease: it produces a lesion directly, bypassing the process that gives rise to comparable damage in patients.
Optokinetic / Optomotor Response
Measures a reflexive head or eye movement tracking a moving pattern, giving a rapid, training-free behavioral estimate of spatial vision and contrast sensitivity in an animal that cannot report them. It is driven largely by reflex circuitry and reports on the visual pathway as a whole, so a deficit it detects still has to be localized by a structural or electrophysiological method, or separated from cortical processing by an operant task.
RPE Cell Transplantation
Places retinal pigment epithelium cells into the subretinal space to supply the supporting functions of that layer, among them outer segment renewal, the visual cycle and the barrier between the choroidal circulation and the outer retina. The deficit it addresses is functional, so it applies where those cells are failing as well as where they have been lost, and what it is meant to preserve is the photoreceptors that depend on their support. That layer sits in an interdependent complex with photoreceptors, Bruch's membrane and the choriocapillaris, so supplying one element of that complex need not restore the rest. Survival, orientation and integration of the graft are the open questions, and a graft that can be seen to survive has not yet been shown to work, so a functional readout is needed alongside the structural one.
Topical Ophthalmic Drug Delivery
A compound applied as drops to the ocular surface. It is non-invasive and repeatable, so it supports frequent dosing without a procedure for each dose. What the route has to establish depends on the target: for an ocular-surface target, residence time and penetration into the surface tissue are the main barriers; for an intraocular anterior-segment target, the compound must cross ocular-surface and corneal or conjunctival barriers and reach an intraocular concentration sufficient for the experiment; for a posterior-segment target, additional ocular barriers separate the surface from the target and posterior-segment exposure is harder to establish.
Which MICRON systems and add-ons appear?
| Instrument | Papers |
|---|---|
| Image-Guided OCT | 4 |
| Insight Software | 4 |
| MICRON IV | 4 |
| MICRON III | 2 |
Which strains and genetic lines are used?
| Strain | Papers | Reported as |
|---|---|---|
| Sprague-Dawley | 4 | Sprague Dawley |
| Brown Norway | 2 | |
| RCS | 1 | |
| RNU | 1 |
Which other species appear alongside?
| Species | Papers |
|---|---|
| Mouse | 2 |
| Cynomolgus Macaque | 1 |
| Rabbit | 1 |
What other conditions are recorded on the same papers?
| Disease | Papers |
|---|---|
| Age-Related Macular Degeneration (General) | 4 |
| Light-Induced Retinal Degeneration | 3 |
| Retinal Pigment Epithelium Dysfunction | 2 |
| Diabetic Retinopathy | 1 |
| Epiretinal Membrane | 1 |
| Retinal Degeneration (General) | 1 |
| Retinal Neovascularization (General) | 1 |
Which MICRON configurations appear in this work?
Configurations recorded in these papers, and the techniques recorded alongside them.
| MICRON configuration | Papers | Most frequent techniques recorded alongside |
|---|---|---|
| Image-Guided OCT | 4 | Electroretinography (4), Optical Coherence Tomography (4), Fundus Fluorescein Angiography (1) |
| Insight Software | 4 | Electroretinography (4), Optical Coherence Tomography (4), Fundus Fluorescein Angiography (1) |
| MICRON IV | 4 | Optical Coherence Tomography (4), Electroretinography (3), Fundus Fluorescein Angiography (1) |
| MICRON III | 2 | Fundus Fluorescein Angiography (2), Optical Coherence Tomography (2), Electroretinography (1) |
The papers
| Year | Title | Journal | Role of focal species | MICRON products | Links |
|---|---|---|---|---|---|
| 2026 | AAV NRF2 gene therapy preserves retinal structure and function in rodent models of oxidative damage. | Molecular Therapy | Disease model | Image-Guided OCT, Insight Software, MICRON IV | DOI · reSEARCH |
| 2025 | Allogeneic RPE cell suspension manufactured at scale demonstrating preclinical safety and efficacy led to IND approval. | npj Regenerative Medicine | Disease model | MICRON IV | DOI · reSEARCH |
| 2020 | Connexin Hemichannel Block Using Orally Delivered Tonabersat Improves Outcomes in Animal Models of Retinal Disease. | Neurotherapeutics | Disease model | Image-Guided OCT, Insight Software, MICRON IV | DOI · reSEARCH |
| 2019 | Low-Luminance Blue Light-Enhanced Phototoxicity in A2E-Laden RPE Cell Cultures and Rats. | International Journal of Molecular Sciences | Disease model | Image-Guided OCT, Insight Software, MICRON III | DOI · reSEARCH |
| 2018 | An Acute Injury Model for the Phenotypic Characteristics of Geographic Atrophy. | Investigative Ophthalmology & Visual Science | Disease model | MICRON III | DOI · reSEARCH |
| 2017 | Tonabersat Prevents Inflammatory Damage in the Central Nervous System by Blocking Connexin43 Hemichannels. | Neurotherapeutics | Disease model | Image-Guided OCT, Insight Software, MICRON IV | DOI · reSEARCH |
Browse all hubs at MICRON Research Hubs. The full corpus is searchable in the reSEARCH portal.